Literature DB >> 22746228

Comparative effectiveness of treatments for cerebral arteriovenous malformations: trends in nationwide outcomes from 2000 to 2009.

Jason M Davies1, Vijay Yanamadala, Michael T Lawton.   

Abstract

OBJECT: The development of multimodality approaches for the treatment of cerebral arteriovenous malformations (AVMs), including microsurgery, endovascular therapy, and radiosurgery, has shifted modern treatment paradigms in the last 10 years. This study examines these changes in detail from a nationwide perspective.
METHODS: The authors examined data from 2001 to 2009 in the Nationwide Inpatient Sample (NIS) database, and they assessed the safety, quality, and cost-effectiveness, including the total number of discharges, discharge proportion, length of stay, and hospital charges. The authors also examined patient demographics (including age, sex, income level, and insurance), hemorrhage status at presentation, and trends in open surgical and endovascular treatment.
RESULTS: A total of 33,997 inpatient admissions for patients with a primary diagnosis of intracranial AVM were identified, with a mean of 4191 patients admitted annually. The mean hospital charges increased 2-fold over the study period without significant differences in outcomes. There were substantial differences between surgical, endovascular, radiosurgical, and multimodality treatments. The proportion of AVMs treated microsurgically remained stable over this period, while the proportion treated endovascularly dramatically increased in size, and the data demonstrate important patient-level distinctions among groups. Outcomes and complication profiles were significantly different between treatment modalities and were impacted by age and hemorrhage status.
CONCLUSIONS: Charges associated with treatment of cerebral AVMs to the payer and society have increased dramatically over the first decade of the 21st century without clear improvements in quality parameters. However, analysis of the 3 primary treatment modalities has demonstrated differences and warrants further investigation to understand which patient population would benefit maximally from each. Unfortunately, with only imprecise measurements of quality in health care delivery, it remains imperative to develop national databases in which parameters, such as survival, functional outcomes, quality of life, and complication rates, can be assessed to examine the value of care delivered in a more meaningful way. Demonstrating an ever-increasing value of delivered health care will be imperative in our evolving health care system.

Entities:  

Mesh:

Year:  2012        PMID: 22746228     DOI: 10.3171/2012.5.FOCUS12107

Source DB:  PubMed          Journal:  Neurosurg Focus        ISSN: 1092-0684            Impact factor:   4.047


  10 in total

1.  Cost determinants in management of brain arteriovenous malformations.

Authors:  Caleb Rutledge; Jeffrey Nelson; Alex Lu; Peyton Nisson; Soren Jonzzon; Ethan A Winkler; Daniel Cooke; Adib A Abla; Michael T Lawton; Helen Kim
Journal:  Acta Neurochir (Wien)       Date:  2019-11-23       Impact factor: 2.216

2.  Intermixed Dimethyl-Sulfoxide-Based Nonadhesive Liquid Embolic Agents Delivered Serially via the Same Microcatheter for Cerebral AVM Treatment.

Authors:  A Sirakov; K Minkin; S Sirakov
Journal:  AJNR Am J Neuroradiol       Date:  2020-03-12       Impact factor: 3.825

3.  Outcomes after intracerebral hemorrhage from arteriovenous malformations.

Authors:  Santosh B Murthy; Alexander E Merkler; Setareh Salehi Omran; Gino Gialdini; Aaron Gusdon; Benjamin Hartley; David Roh; Halinder S Mangat; Costantino Iadecola; Babak B Navi; Hooman Kamel
Journal:  Neurology       Date:  2017-04-19       Impact factor: 9.910

4.  Extradural, retro-orbital, arteriovenous malformation as the cause of a long-term history of syncope.

Authors:  Gian Piero Carboni; Carlo Cosimo Quattrocchi
Journal:  BMJ Case Rep       Date:  2012-11-28

5.  Morbidity and healthcare costs of vascular anomalies: a national study.

Authors:  Jina Kim; Zhifei Sun; Harold J Leraas; Uttara P Nag; Ehsan Benrashid; Alexander C Allori; Waleska M Pabon-Ramos; Henry E Rice; Cynthia K Shortell; Elisabeth T Tracy
Journal:  Pediatr Surg Int       Date:  2016-11-22       Impact factor: 1.827

6.  Effect of A Randomized trial of Unruptured Brain Arteriovenous Malformation on Interventional Treatment Rates for Unruptured Arteriovenous Malformations.

Authors:  Alexandra S Reynolds; Monica L Chen; Alexander E Merkler; Abhinaba Chatterjee; Iván Díaz; Babak B Navi; Hooman Kamel
Journal:  Cerebrovasc Dis       Date:  2019-08-21       Impact factor: 2.762

7.  Validation of an International Classification of Disease, Ninth Revision coding algorithm to identify decompressive craniectomy for stroke.

Authors:  Hormuzdiyar H Dasenbrock; David J Cote; Yuri Pompeu; Viren S Vasudeva; Timothy R Smith; William B Gormley
Journal:  BMC Neurol       Date:  2017-06-26       Impact factor: 2.474

8.  Microsurgery for intracranial arteriovenous malformation: Long-term outcomes in 445 patients.

Authors:  Qingqing Ren; Min He; Yunhui Zeng; Zhiyong Liu; Hao Liu; Jianguo Xu
Journal:  PLoS One       Date:  2017-03-21       Impact factor: 3.240

9.  Cerebral arteriovenous malformations - usability of Spetzler-Martin and Spetzler-Ponce scales in qualification to endovascular embolisation and neurosurgical procedure.

Authors:  Mariusz Hofman; Tomasz Jamróz; Izabela Kołodziej; Jakub Jaskólski; Aleksandra Ignatowicz; Izabela Jakutowicz; Nikodem Przybyłko; Damian Kocur; Jan Baron
Journal:  Pol J Radiol       Date:  2018-05-29

10.  Treatment of Brain AVMs (TOBAS): study protocol for a pragmatic randomized controlled trial.

Authors:  Tim E Darsaut; Elsa Magro; Jean-Christophe Gentric; André Lima Batista; Chiraz Chaalala; David Roberge; Michel W Bojanowski; Alain Weill; Daniel Roy; Jean Raymond
Journal:  Trials       Date:  2015-11-04       Impact factor: 2.279

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.